Novogene Co., Ltd. (SHA:688315)
China
· Delayed Price · Currency is CNY 13.67
+0.16 (1.18%)
May 23, 2025, 2:45 PM CST
Novogene Revenue
Novogene had revenue of 502.01M CNY in the quarter ending March 31, 2025, with 7.16% growth. This brings the company's revenue in the last twelve months to 2.14B, up 5.66% year-over-year. In the year 2024, Novogene had annual revenue of 2.11B with 5.45% growth.
Revenue (ttm)
2.14B
Revenue Growth
+5.66%
P/S Ratio
2.57
Revenue / Employee
974.05K
Employees
2,202
Market Cap
5.52B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.11B | 109.21M | 5.45% |
| Dec 31, 2023 | 2.00B | 76.47M | 3.97% |
| Dec 31, 2022 | 1.93B | 59.24M | 3.17% |
| Dec 31, 2021 | 1.87B | 376.37M | 25.26% |
| Dec 31, 2020 | 1.49B | -44.80M | -2.92% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Hengrui Medicine | 29.19B |
| Shenzhen Mindray Bio-Medical Electronics | 35.59B |
| WuXi AppTec | 39.59B |
| Zhangzhou Pientzehuang Pharmaceutical., | 10.76B |
| Aier Eye Hospital Group | 21.81B |
| Shanghai United Imaging Healthcare | 10.43B |
| Sichuan Biokin Pharmaceutical | 5.82B |
| Yunnan Baiyao Group Co.,Ltd | 40.10B |